

Mumbai, August 12, 2014

Wockhardt Q1FY15 Net Sales at Rs.991 crore and PAT at Rs.20 crore

	Q1-FY15		Q1-FY14	FY14
	Apr - Jun 2014		Apr - Jun 2013	
	Rsc	Gwth Y-O-Y	Rsc	Rsc
Sales	991	-27%	1,358	4,830
R&D	111	13%	98	403
R&D % to Sales	11.2%		7.2%	8.3%
Operating Profit	61	-86%	421	980
Op. Profit Margins %	6.2%		31.0%	20%
Profit After Tax	20	-94%	324	841
PAT Margins	2.0%		23.9%	17%
EPS	1.8		29.6	6.7

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1st quarter results for Financial Year 2015, today.

Quarter ended 30th June 2014

Consolidated revenue for the quarter was Rs.991 crore and Profit After Tax was at Rs.20 crore.

The company increased its Research spend significantly and the same is now at 11.2% to sales at Rs.111 crores and including capital expenditure is at 11.7% to sales for the quarter.

Wockhardt filed 13 new product applications with USFDA in Q1FY15 taking cumulative filings pending approval to 75.

PRESS RELEASE

Wockhardt also filed for 52 patents during the quarter taking the cumulative filings to 2053 and has been granted 25 patents during the quarter taking the cumulative patents granted to 284.

Capex

Capital expenditure of Rs.67 crores was incurred in Q1FY15.

Business Highlights

The India business recorded a growth of 18% in Q1FY15. Emerging Markets business grew by 10% in Q1FY15.

Wockhardt's International Business contributed 70% of the Total Revenues during the quarter.

The UK business remained flat in Q1FY15. The Irish market recorded a growth of 13% in Q1FY15.

Wockhardt's US business declined by 60% in Q1FY15 and contributed 29% of the Global Revenues for Wockhardt in Q1FY15.

Wockhardt launched 16 new products in Domestic Market in Q1FY15.

About Wockhardt :

Wockhardt is a highly technology intensive global pharmaceutical and biotechnology company. It's multi-disciplinary and innovative R&D programmes globally, are strongly focused on creating Intellectual Properties. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 79% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 850 scientists, of whom 80 are doctorates. In all, Wockhardt has 284 Patents granted worldwide. In biotechnology research, it has built competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 8,600 people from 21 different nationalities.